Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Item
http://www.wikidata.org/entity/Q34110309
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.The era of bioengineering: how will this affect the next generation of cancer immunotherapy?New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?Delivery System of CpG Oligodeoxynucleotides through Eliciting an Effective T cell Immune Response against Melanoma in Mice.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Potential approaches for more successful dendritic cell-based immunotherapy.Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?Assessment of tumor antigen-loaded solid lipid nanoparticles as an efficient delivery system for dendritic cell engineering.
P2860

Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Item
http://www.wikidata.org/entity/Q34110309
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@ast
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@en
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@nl
type
label
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@ast
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@en
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@nl
prefLabel
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@ast
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@en
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Day-4 myeloid dendritic cells ...... t potent anti-tumor responses.
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0028732
P407
P433
P478
P50
P577
P5875
P698
P932